New drug targets hidden leukemia cells in patients who failed standard care
NCT ID NCT05285813
Summary
This study tests an experimental drug called vibecotamab in adults with two types of blood cancer: acute myeloid leukemia (AML) that still shows tiny amounts of cancer after treatment, and myelodysplastic syndrome (MDS) that has stopped responding to standard medications. The goal is to see if vibecotamab can eliminate these remaining cancer cells or control the disease. Researchers will monitor how well the drug works and its safety in 42 participants at MD Anderson Cancer Center.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.